NEW YORK – Tempus AI said Wednesday that it has inked a multiyear collaboration with immunotherapy company BioNTech.
Under the agreement, Chicago-based Tempus will provide its real-world multimodal datasets, analytical support, and computational biology expertise to support the development of BioNTech's oncology pipeline by helping to generate insights into the biological mechanisms behind new therapies.
"By applying Tempus' extensive real-world multimodal data to BioNTech's AI capabilities and multi-platform discovery engine, we believe we can generate a real impact by working to bring novel therapies to those cancer patients who could potentially benefit the most," Tempus Chief Operating Officer Ryan Fukushima said in a statement.
According to its website, Tempus offers real-world molecular data, including tumor/normal DNA and whole-transcriptome RNA sequencing; clinical data such as diagnosis, treatments, and clinical outcomes; and pathology slide imaging data, including parameters based on immunohistochemistry and hematoxylin and eosin assessments.
Financial terms of the agreement were not disclosed.